| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 72 | 2025 | 1188 | 11.660 |
Why?
|
| Brain Ischemia | 51 | 2024 | 417 | 10.930 |
Why?
|
| Leukoaraiosis | 13 | 2019 | 45 | 5.790 |
Why?
|
| Thrombectomy | 27 | 2025 | 227 | 5.040 |
Why?
|
| Brain Injuries, Traumatic | 7 | 2025 | 94 | 4.070 |
Why?
|
| Infarction, Middle Cerebral Artery | 21 | 2025 | 84 | 3.750 |
Why?
|
| White Matter | 7 | 2020 | 123 | 3.620 |
Why?
|
| Endovascular Procedures | 27 | 2025 | 643 | 3.260 |
Why?
|
| Tissue Plasminogen Activator | 13 | 2024 | 126 | 3.180 |
Why?
|
| Atrial Fibrillation | 15 | 2024 | 834 | 3.000 |
Why?
|
| Thrombolytic Therapy | 16 | 2025 | 190 | 2.980 |
Why?
|
| Severity of Illness Index | 19 | 2024 | 1541 | 2.760 |
Why?
|
| Retrospective Studies | 67 | 2025 | 6535 | 2.620 |
Why?
|
| Fibrinolytic Agents | 13 | 2025 | 169 | 2.610 |
Why?
|
| Cerebrovascular Circulation | 18 | 2024 | 178 | 2.540 |
Why?
|
| Anticoagulants | 16 | 2025 | 493 | 2.480 |
Why?
|
| Aged, 80 and over | 55 | 2025 | 5406 | 2.480 |
Why?
|
| Male | 126 | 2025 | 29483 | 2.470 |
Why?
|
| Aged | 85 | 2025 | 14254 | 2.410 |
Why?
|
| Intracranial Hemorrhages | 8 | 2024 | 65 | 2.390 |
Why?
|
| Treatment Outcome | 63 | 2025 | 5590 | 2.280 |
Why?
|
| Brain Concussion | 4 | 2023 | 35 | 2.170 |
Why?
|
| Middle Aged | 79 | 2025 | 17363 | 2.000 |
Why?
|
| Embolism | 6 | 2020 | 41 | 1.910 |
Why?
|
| Disease Models, Animal | 22 | 2025 | 2174 | 1.900 |
Why?
|
| Female | 93 | 2025 | 32488 | 1.830 |
Why?
|
| Cerebral Infarction | 10 | 2022 | 83 | 1.830 |
Why?
|
| Brain | 21 | 2023 | 1550 | 1.800 |
Why?
|
| Humans | 132 | 2025 | 62678 | 1.650 |
Why?
|
| Heart Diseases | 3 | 2022 | 215 | 1.640 |
Why?
|
| Magnetic Resonance Imaging | 28 | 2022 | 2147 | 1.580 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 15 | 2021 | 152 | 1.570 |
Why?
|
| Amyotrophic Lateral Sclerosis | 4 | 2025 | 507 | 1.520 |
Why?
|
| Recovery of Function | 9 | 2019 | 283 | 1.520 |
Why?
|
| Intracranial Thrombosis | 9 | 2024 | 28 | 1.510 |
Why?
|
| Mechanical Thrombolysis | 4 | 2024 | 35 | 1.460 |
Why?
|
| Venous Thrombosis | 7 | 2024 | 113 | 1.420 |
Why?
|
| Armadillo Domain Proteins | 2 | 2025 | 23 | 1.410 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2015 | 116 | 1.380 |
Why?
|
| Carotid Artery, Internal, Dissection | 8 | 2025 | 16 | 1.360 |
Why?
|
| Risk Factors | 31 | 2025 | 5302 | 1.360 |
Why?
|
| Cytoskeletal Proteins | 2 | 2025 | 200 | 1.300 |
Why?
|
| Brain Injuries | 4 | 2020 | 140 | 1.230 |
Why?
|
| Ischemic Attack, Transient | 8 | 2024 | 96 | 1.210 |
Why?
|
| Neuroimaging | 8 | 2022 | 154 | 1.170 |
Why?
|
| Rats | 28 | 2018 | 1978 | 1.160 |
Why?
|
| Long QT Syndrome | 2 | 2021 | 31 | 1.130 |
Why?
|
| Superoxide Dismutase-1 | 2 | 2025 | 144 | 1.110 |
Why?
|
| Carotid Stenosis | 3 | 2024 | 105 | 1.110 |
Why?
|
| Time Factors | 25 | 2024 | 3742 | 1.040 |
Why?
|
| Reperfusion | 7 | 2024 | 37 | 1.040 |
Why?
|
| Animals | 49 | 2025 | 20579 | 1.030 |
Why?
|
| Cost of Illness | 3 | 2015 | 161 | 1.000 |
Why?
|
| Cortical Spreading Depression | 4 | 2020 | 7 | 0.990 |
Why?
|
| Vertebral Artery Dissection | 5 | 2025 | 15 | 0.990 |
Why?
|
| Brain Infarction | 5 | 2021 | 21 | 0.980 |
Why?
|
| Aspirin | 4 | 2025 | 171 | 0.960 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2025 | 225 | 0.950 |
Why?
|
| Registries | 14 | 2025 | 872 | 0.910 |
Why?
|
| Frontotemporal Dementia | 2 | 2023 | 149 | 0.910 |
Why?
|
| Pick Disease of the Brain | 1 | 2023 | 6 | 0.870 |
Why?
|
| Predictive Value of Tests | 9 | 2024 | 1077 | 0.860 |
Why?
|
| C9orf72 Protein | 2 | 2023 | 114 | 0.840 |
Why?
|
| Geniculate Bodies | 1 | 2023 | 2 | 0.840 |
Why?
|
| Axons | 3 | 2023 | 123 | 0.810 |
Why?
|
| Cerebral Hemorrhage | 8 | 2025 | 93 | 0.800 |
Why?
|
| Pancreatitis | 1 | 2023 | 97 | 0.780 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2025 | 1589 | 0.770 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 217 | 0.770 |
Why?
|
| Prognosis | 12 | 2024 | 1724 | 0.760 |
Why?
|
| Chronic Traumatic Encephalopathy | 1 | 2021 | 5 | 0.730 |
Why?
|
| Neurons | 6 | 2023 | 909 | 0.730 |
Why?
|
| Tauopathies | 1 | 2021 | 19 | 0.720 |
Why?
|
| Intracranial Embolism | 5 | 2014 | 39 | 0.700 |
Why?
|
| Troponin | 2 | 2020 | 38 | 0.690 |
Why?
|
| Risk Assessment | 11 | 2024 | 2039 | 0.680 |
Why?
|
| Electroencephalography | 3 | 2020 | 147 | 0.680 |
Why?
|
| Electrocardiography | 2 | 2021 | 550 | 0.660 |
Why?
|
| Rats, Wistar | 12 | 2017 | 185 | 0.650 |
Why?
|
| Vitamin K | 1 | 2019 | 16 | 0.640 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2010 | 622 | 0.630 |
Why?
|
| Weight Loss | 1 | 2021 | 272 | 0.630 |
Why?
|
| Cognition | 2 | 2022 | 481 | 0.620 |
Why?
|
| Mice | 12 | 2025 | 10802 | 0.620 |
Why?
|
| Hematoma | 1 | 2019 | 77 | 0.610 |
Why?
|
| Recurrence | 9 | 2025 | 634 | 0.610 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 25 | 0.610 |
Why?
|
| Propensity Score | 5 | 2025 | 154 | 0.600 |
Why?
|
| Reperfusion Injury | 3 | 2021 | 53 | 0.590 |
Why?
|
| Stroke Rehabilitation | 1 | 2019 | 50 | 0.590 |
Why?
|
| Disability Evaluation | 4 | 2024 | 214 | 0.590 |
Why?
|
| Diffuse Axonal Injury | 1 | 2018 | 4 | 0.590 |
Why?
|
| Adult | 23 | 2025 | 16625 | 0.580 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2018 | 9 | 0.580 |
Why?
|
| Nucleic Acids | 1 | 2019 | 60 | 0.580 |
Why?
|
| Hyperoxia | 2 | 2008 | 17 | 0.570 |
Why?
|
| Lateral Ventricles | 1 | 2017 | 7 | 0.550 |
Why?
|
| Warfarin | 4 | 2024 | 109 | 0.550 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 164 | 0.540 |
Why?
|
| Length of Stay | 2 | 2019 | 804 | 0.540 |
Why?
|
| Stroke Volume | 1 | 2018 | 328 | 0.530 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 268 | 0.530 |
Why?
|
| Motor Activity | 2 | 2019 | 343 | 0.520 |
Why?
|
| Thrombophilia | 2 | 2020 | 14 | 0.520 |
Why?
|
| Eligibility Determination | 1 | 2016 | 36 | 0.510 |
Why?
|
| Alzheimer Disease | 2 | 2022 | 718 | 0.510 |
Why?
|
| Hemorrhage | 7 | 2024 | 266 | 0.510 |
Why?
|
| Cerebrum | 1 | 2015 | 16 | 0.490 |
Why?
|
| Stroke, Lacunar | 1 | 2015 | 4 | 0.480 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 108 | 0.480 |
Why?
|
| Post-Concussion Syndrome | 1 | 2015 | 5 | 0.480 |
Why?
|
| Myxoma | 1 | 2015 | 13 | 0.470 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 313 | 0.470 |
Why?
|
| Embolism, Paradoxical | 1 | 2015 | 13 | 0.470 |
Why?
|
| Critical Care | 1 | 2019 | 389 | 0.470 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 13 | 0.470 |
Why?
|
| Glasgow Outcome Scale | 1 | 2014 | 17 | 0.470 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 42 | 0.470 |
Why?
|
| Heart Neoplasms | 1 | 2015 | 33 | 0.460 |
Why?
|
| Patient Selection | 2 | 2016 | 482 | 0.450 |
Why?
|
| Middle Cerebral Artery | 4 | 2018 | 46 | 0.440 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 106 | 0.440 |
Why?
|
| Infarction | 3 | 2023 | 20 | 0.440 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2012 | 74 | 0.430 |
Why?
|
| Vitamin D | 1 | 2015 | 139 | 0.430 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2013 | 7 | 0.430 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 45 | 0.430 |
Why?
|
| Myocardial Infarction | 2 | 2024 | 910 | 0.430 |
Why?
|
| Sinus Thrombosis, Intracranial | 2 | 2024 | 7 | 0.430 |
Why?
|
| Cerebral Arterial Diseases | 2 | 2011 | 8 | 0.430 |
Why?
|
| Temporal Lobe | 1 | 2013 | 46 | 0.430 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2013 | 24 | 0.420 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 933 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 708 | 0.410 |
Why?
|
| Behavior, Animal | 4 | 2007 | 228 | 0.410 |
Why?
|
| Venous Thromboembolism | 3 | 2024 | 147 | 0.400 |
Why?
|
| Mice, Knockout | 3 | 2025 | 2097 | 0.400 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 25 | 0.400 |
Why?
|
| Brain Death | 1 | 2012 | 16 | 0.400 |
Why?
|
| Cohort Studies | 9 | 2024 | 2539 | 0.390 |
Why?
|
| Mice, Transgenic | 3 | 2025 | 1271 | 0.390 |
Why?
|
| Stents | 3 | 2025 | 487 | 0.380 |
Why?
|
| Neuroprotective Agents | 3 | 2009 | 75 | 0.380 |
Why?
|
| Linear Models | 4 | 2020 | 409 | 0.380 |
Why?
|
| Cell Death | 4 | 2007 | 280 | 0.370 |
Why?
|
| Anesthesia, General | 2 | 2024 | 45 | 0.360 |
Why?
|
| Coma | 1 | 2011 | 13 | 0.360 |
Why?
|
| Sex Characteristics | 1 | 2012 | 203 | 0.360 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2014 | 667 | 0.350 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 2018 | 6 | 0.350 |
Why?
|
| Heart Failure | 1 | 2018 | 900 | 0.340 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 453 | 0.340 |
Why?
|
| Logistic Models | 4 | 2020 | 1273 | 0.330 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2010 | 8 | 0.330 |
Why?
|
| Maze Learning | 2 | 2007 | 52 | 0.330 |
Why?
|
| Functional Laterality | 2 | 2007 | 138 | 0.330 |
Why?
|
| United States | 8 | 2025 | 7719 | 0.320 |
Why?
|
| Acute Disease | 3 | 2023 | 670 | 0.320 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 39 | 0.320 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2009 | 2 | 0.320 |
Why?
|
| Head Injuries, Closed | 2 | 2021 | 15 | 0.320 |
Why?
|
| Spatial Behavior | 2 | 2007 | 8 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 3387 | 0.320 |
Why?
|
| Hyperbaric Oxygenation | 2 | 2006 | 16 | 0.310 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1070 | 0.310 |
Why?
|
| Neuropsychological Tests | 2 | 2022 | 389 | 0.310 |
Why?
|
| Autophagy | 2 | 2021 | 225 | 0.300 |
Why?
|
| Prospective Studies | 5 | 2024 | 3258 | 0.300 |
Why?
|
| Disease Progression | 3 | 2025 | 1159 | 0.300 |
Why?
|
| Patient Admission | 3 | 2020 | 190 | 0.300 |
Why?
|
| Age Factors | 5 | 2024 | 1554 | 0.290 |
Why?
|
| Carcinoma | 1 | 2009 | 125 | 0.290 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 83 | 0.290 |
Why?
|
| Analysis of Variance | 4 | 2015 | 608 | 0.290 |
Why?
|
| Circle of Willis | 1 | 2007 | 7 | 0.280 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 2445 | 0.280 |
Why?
|
| Nerve Fibers | 1 | 2007 | 30 | 0.280 |
Why?
|
| Incidence | 5 | 2025 | 1367 | 0.280 |
Why?
|
| Electrophysiology | 1 | 2007 | 89 | 0.270 |
Why?
|
| Discrimination Learning | 1 | 2007 | 11 | 0.270 |
Why?
|
| Levodopa | 1 | 2007 | 8 | 0.270 |
Why?
|
| Hyperhomocysteinemia | 1 | 2007 | 6 | 0.270 |
Why?
|
| Nitrous Oxide | 1 | 2007 | 7 | 0.270 |
Why?
|
| Hypotension | 1 | 2007 | 50 | 0.270 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 156 | 0.260 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2007 | 35 | 0.260 |
Why?
|
| Radiography | 3 | 2019 | 536 | 0.260 |
Why?
|
| DNA Repeat Expansion | 2 | 2023 | 58 | 0.260 |
Why?
|
| Prevalence | 4 | 2020 | 1348 | 0.250 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 30 | 0.250 |
Why?
|
| RNA, Small Interfering | 2 | 2025 | 898 | 0.250 |
Why?
|
| Boronic Acids | 1 | 2006 | 28 | 0.250 |
Why?
|
| Cerebral Angiography | 4 | 2022 | 289 | 0.250 |
Why?
|
| Pyrazines | 1 | 2006 | 34 | 0.250 |
Why?
|
| Biomarkers | 4 | 2020 | 1385 | 0.250 |
Why?
|
| Hippocampus | 2 | 2007 | 267 | 0.250 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1139 | 0.250 |
Why?
|
| Brain Edema | 2 | 2021 | 31 | 0.250 |
Why?
|
| Administration, Oral | 3 | 2025 | 366 | 0.240 |
Why?
|
| Diffusion | 5 | 2010 | 83 | 0.240 |
Why?
|
| Infarction, Anterior Cerebral Artery | 1 | 2025 | 3 | 0.240 |
Why?
|
| Thromboembolism | 1 | 2006 | 72 | 0.240 |
Why?
|
| Blood Pressure | 4 | 2010 | 513 | 0.240 |
Why?
|
| Tetrazolium Salts | 4 | 2009 | 15 | 0.240 |
Why?
|
| Research | 1 | 2007 | 192 | 0.240 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 415 | 0.230 |
Why?
|
| Posterior Cerebral Artery | 1 | 2024 | 12 | 0.230 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2024 | 25 | 0.230 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 422 | 0.220 |
Why?
|
| Telemedicine | 1 | 2009 | 318 | 0.220 |
Why?
|
| Conscious Sedation | 1 | 2024 | 39 | 0.220 |
Why?
|
| Secondary Prevention | 2 | 2021 | 163 | 0.220 |
Why?
|
| Blood Glucose | 2 | 2020 | 485 | 0.210 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 117 | 0.210 |
Why?
|
| Astrocytes | 2 | 2021 | 119 | 0.210 |
Why?
|
| Echocardiography | 2 | 2018 | 498 | 0.210 |
Why?
|
| Epilepsy | 1 | 2024 | 110 | 0.210 |
Why?
|
| Mortality | 2 | 2021 | 160 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 233 | 0.210 |
Why?
|
| Endarterectomy, Carotid | 1 | 2024 | 91 | 0.210 |
Why?
|
| Skull | 1 | 2023 | 51 | 0.200 |
Why?
|
| Massachusetts | 2 | 2020 | 2061 | 0.200 |
Why?
|
| Blindness | 1 | 2023 | 41 | 0.200 |
Why?
|
| Cerebral Revascularization | 2 | 2024 | 30 | 0.200 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2022 | 22 | 0.200 |
Why?
|
| Vision Disorders | 1 | 2023 | 64 | 0.200 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 37 | 0.200 |
Why?
|
| Simvastatin | 1 | 2022 | 27 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 729 | 0.190 |
Why?
|
| Rats, Inbred WKY | 3 | 2014 | 11 | 0.190 |
Why?
|
| Dabigatran | 1 | 2022 | 20 | 0.190 |
Why?
|
| Reflex | 1 | 2021 | 27 | 0.190 |
Why?
|
| Arginine | 1 | 2022 | 122 | 0.190 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1184 | 0.190 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 212 | 0.180 |
Why?
|
| RNA Interference | 1 | 2025 | 618 | 0.180 |
Why?
|
| Administration, Intravenous | 3 | 2025 | 66 | 0.170 |
Why?
|
| Mean Platelet Volume | 1 | 2020 | 2 | 0.170 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 700 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2016 | 576 | 0.170 |
Why?
|
| Survival Rate | 3 | 2020 | 839 | 0.170 |
Why?
|
| Hydrocephalus | 1 | 2020 | 43 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2020 | 39 | 0.170 |
Why?
|
| Bed Rest | 1 | 2019 | 11 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 78 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2020 | 104 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 173 | 0.160 |
Why?
|
| CADASIL | 1 | 2019 | 3 | 0.160 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 108 | 0.150 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 139 | 0.150 |
Why?
|
| Neurologic Examination | 1 | 2019 | 52 | 0.150 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 1638 | 0.150 |
Why?
|
| Trauma Severity Indices | 1 | 2018 | 34 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 178 | 0.150 |
Why?
|
| Attention | 1 | 2019 | 148 | 0.140 |
Why?
|
| Random Allocation | 3 | 2007 | 197 | 0.140 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 85 | 0.140 |
Why?
|
| Huntingtin Protein | 1 | 2018 | 141 | 0.140 |
Why?
|
| Optical Imaging | 1 | 2018 | 71 | 0.140 |
Why?
|
| Regional Blood Flow | 2 | 2008 | 111 | 0.140 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2019 | 221 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2011 | 185 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 203 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 294 | 0.130 |
Why?
|
| Adolescent | 3 | 2023 | 6172 | 0.130 |
Why?
|
| Neurosurgery | 1 | 2017 | 29 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 217 | 0.130 |
Why?
|
| Neurology | 1 | 2017 | 40 | 0.130 |
Why?
|
| Specialization | 1 | 2017 | 81 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 118 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 41 | 0.130 |
Why?
|
| Wallerian Degeneration | 1 | 2016 | 8 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 964 | 0.120 |
Why?
|
| Plasminogen Activators | 1 | 2015 | 10 | 0.120 |
Why?
|
| Corpus Callosum | 1 | 2016 | 42 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2017 | 220 | 0.120 |
Why?
|
| Catheters | 1 | 2016 | 74 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2016 | 93 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 663 | 0.120 |
Why?
|
| Immunohistochemistry | 3 | 2006 | 890 | 0.120 |
Why?
|
| Hospitalization | 2 | 2020 | 1344 | 0.120 |
Why?
|
| Glasgow Coma Scale | 1 | 2014 | 46 | 0.120 |
Why?
|
| Software | 2 | 2009 | 381 | 0.120 |
Why?
|
| Intracranial Aneurysm | 1 | 2019 | 363 | 0.110 |
Why?
|
| Oxygen | 3 | 2022 | 316 | 0.110 |
Why?
|
| Young Adult | 3 | 2022 | 4633 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2016 | 768 | 0.110 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 21 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2017 | 405 | 0.110 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 246 | 0.110 |
Why?
|
| Dementia | 1 | 2017 | 258 | 0.110 |
Why?
|
| Amyloid beta-Peptides | 1 | 2016 | 297 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 265 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2016 | 217 | 0.110 |
Why?
|
| Neoplasms | 1 | 2024 | 1350 | 0.110 |
Why?
|
| ROC Curve | 1 | 2014 | 277 | 0.100 |
Why?
|
| Comorbidity | 3 | 2024 | 1118 | 0.100 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2012 | 6 | 0.100 |
Why?
|
| Research Design | 1 | 2016 | 572 | 0.100 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 2012 | 3 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 497 | 0.100 |
Why?
|
| Nasopharynx | 1 | 2012 | 22 | 0.100 |
Why?
|
| Motor Neurons | 2 | 2025 | 212 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 220 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 186 | 0.090 |
Why?
|
| Dysarthria | 1 | 2011 | 7 | 0.090 |
Why?
|
| Teaching | 1 | 2012 | 156 | 0.090 |
Why?
|
| Carotid Artery, Internal | 2 | 2024 | 68 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 337 | 0.090 |
Why?
|
| Thalamus | 1 | 2011 | 66 | 0.090 |
Why?
|
| New York City | 2 | 2020 | 79 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 207 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2025 | 865 | 0.080 |
Why?
|
| Reaction Time | 2 | 2007 | 124 | 0.080 |
Why?
|
| Gene Silencing | 2 | 2025 | 392 | 0.080 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2009 | 14 | 0.080 |
Why?
|
| Dogs | 2 | 2022 | 324 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2009 | 41 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 1221 | 0.080 |
Why?
|
| Magnetic Field Therapy | 1 | 2008 | 3 | 0.080 |
Why?
|
| Computed Tomography Angiography | 2 | 2022 | 123 | 0.080 |
Why?
|
| Ganglia, Parasympathetic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Cerebral Cortex | 2 | 2006 | 256 | 0.070 |
Why?
|
| Injury Severity Score | 1 | 2007 | 104 | 0.070 |
Why?
|
| Spectrum Analysis | 1 | 2007 | 51 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2009 | 174 | 0.070 |
Why?
|
| Space Perception | 1 | 2007 | 19 | 0.070 |
Why?
|
| Catechols | 1 | 2007 | 6 | 0.070 |
Why?
|
| Homocysteine | 1 | 2007 | 33 | 0.070 |
Why?
|
| Silicon | 1 | 2006 | 18 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 370 | 0.070 |
Why?
|
| Immunoassay | 1 | 2007 | 70 | 0.070 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2009 | 232 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 40 | 0.070 |
Why?
|
| Sutures | 1 | 2006 | 41 | 0.070 |
Why?
|
| Nitriles | 1 | 2007 | 69 | 0.070 |
Why?
|
| Coloring Agents | 2 | 2023 | 54 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2007 | 127 | 0.070 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2007 | 57 | 0.070 |
Why?
|
| Perfusion | 1 | 2006 | 73 | 0.070 |
Why?
|
| Sensation Disorders | 1 | 2006 | 21 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2006 | 23 | 0.070 |
Why?
|
| Autoradiography | 1 | 2006 | 53 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 725 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2022 | 463 | 0.060 |
Why?
|
| Bortezomib | 1 | 2006 | 56 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 318 | 0.060 |
Why?
|
| Surface Properties | 1 | 2006 | 278 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 130 | 0.060 |
Why?
|
| Pregnancy | 2 | 2022 | 2316 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 115 | 0.060 |
Why?
|
| Proteomics | 1 | 2007 | 284 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 373 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 40 | 0.060 |
Why?
|
| Heart Rate | 1 | 2005 | 319 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2024 | 299 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2025 | 227 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2023 | 45 | 0.050 |
Why?
|
| Intravital Microscopy | 1 | 2023 | 12 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2024 | 66 | 0.050 |
Why?
|
| Arteries | 1 | 2024 | 81 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 761 | 0.050 |
Why?
|
| Headache | 1 | 2023 | 58 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2022 | 20 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2022 | 25 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2022 | 11 | 0.050 |
Why?
|
| Head | 1 | 2023 | 55 | 0.050 |
Why?
|
| Dipeptides | 1 | 2022 | 67 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 562 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2024 | 194 | 0.050 |
Why?
|
| Inpatients | 1 | 2024 | 302 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 308 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2024 | 852 | 0.050 |
Why?
|
| Alberta | 1 | 2020 | 5 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2024 | 505 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2025 | 429 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 7 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2022 | 195 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 129 | 0.040 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 8 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 122 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2020 | 31 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 13 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 36 | 0.040 |
Why?
|
| Mutation | 1 | 2009 | 2573 | 0.040 |
Why?
|
| Migraine with Aura | 1 | 2020 | 2 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 58 | 0.040 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2020 | 46 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 118 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2021 | 134 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 205 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 416 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 422 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 469 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2018 | 19 | 0.040 |
Why?
|
| Mannitol | 1 | 2018 | 14 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2022 | 349 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 726 | 0.040 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 31 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2018 | 61 | 0.040 |
Why?
|
| Phosphorylcholine | 1 | 2018 | 44 | 0.040 |
Why?
|
| Smoking | 1 | 2022 | 864 | 0.040 |
Why?
|
| Light | 1 | 2018 | 201 | 0.030 |
Why?
|
| International Agencies | 1 | 2017 | 7 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 260 | 0.030 |
Why?
|
| Hypercapnia | 2 | 2006 | 9 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2016 | 74 | 0.030 |
Why?
|
| Suction | 1 | 2016 | 34 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 375 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 109 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2017 | 153 | 0.030 |
Why?
|
| Brain Mapping | 2 | 2007 | 232 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 220 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 348 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 366 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 341 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 371 | 0.030 |
Why?
|
| Curriculum | 1 | 2017 | 585 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 70 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2018 | 771 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 2011 | 5 | 0.020 |
Why?
|
| Annexin A2 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Fibrin | 1 | 2011 | 19 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2011 | 32 | 0.020 |
Why?
|
| Xenon Isotopes | 1 | 2010 | 3 | 0.020 |
Why?
|
| Protons | 1 | 2010 | 62 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2540 | 0.020 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2009 | 14 | 0.020 |
Why?
|
| Proteinuria | 1 | 2009 | 41 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2648 | 0.020 |
Why?
|
| Brain Damage, Chronic | 1 | 2006 | 5 | 0.020 |
Why?
|
| Perceptual Disorders | 1 | 2006 | 8 | 0.020 |
Why?
|
| Kidney | 1 | 2009 | 444 | 0.020 |
Why?
|
| Sensation | 1 | 2006 | 19 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 2006 | 86 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 383 | 0.020 |
Why?
|
| Nerve Net | 1 | 2006 | 97 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 137 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 1191 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 334 | 0.010 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2004 | 2 | 0.010 |
Why?
|
| Ischemia | 1 | 2005 | 203 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2004 | 294 | 0.010 |
Why?
|